Atorvastatin Calcium Hydrate/Ramipril

阿托伐他汀钙/雷米普利

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAtorvastatin Calcium Hydrate/Ramipril
Drug Alias NameAtorvastatin Calcium Hydrate•Ramipril阿托伐他汀钙雷米普利雷米普利/阿托伐他汀钙Atorvastatin Calcium /Ramipril阿托伐他汀钙和雷米普利 +[9] 
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsAngiotensin-converting enzyme inhibitors
TargetsAngiotensin-converting enzymeHMG-CoA reductase
Therapy Area/IndicationsHypercholesterolemiaHypertension
Global Approved IndicationsHypercholesterolemiaHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2008/05/01
Country/TerritoryIndia
CombinationsYes RamiprilAtorvastatin Calcium Hydrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDr.Reddy's Laboratories Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDr.Reddy's Laboratories Ltd
Inactive CompaniesN/A
Active IndicationsHypercholesterolemiaHypertension
Inactive IndicationsN/A

Other Information

ATC CodeC10BA
Related LinksN/A